Progress of Phage Therapy for Acne Vulgaris

Phage therapy presents a promising alternative for treating acne vulgaris by specifically targeting Cutibacterium acnes, the core pathogenic factor in acne. Unlike traditional treatments, which can lead to antibiotic resistance and adverse reactions, bacteriophages offer high safety and low resistance risk. The article reviews the pathogenesis of acne, limitations of current therapies, and the potential of bacteriophages, including their ability to lyse C. acnes and inhibit biofilm formation. While preclinical and Phase I trials show safety and preliminary efficacy, further large-scale trials and mechanistic studies are needed. Future efforts should focus on microbiome-based strategies and improving regulatory frameworks to enhance clinical translation of phage therapy.